Justin Zelin
Stock Analyst at BTIG
(1.43)
# 3,368
Out of 4,834 analysts
37
Total ratings
21.21%
Success rate
-0.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.67 | +124.72% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $17.82 | +135.69% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.18 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $17.32 | +257.97% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $4.87 | +1,748.05% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.31 | +819.54% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.11 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $27.40 | +356.20% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $7.93 | +240.48% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.13 | +70,696.46% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.06 | +213.15% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.64 | +1,467.40% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.85 | +1,783.02% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $7.64 | +384.29% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $8.95 | +291.06% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $27.69 | +225.03% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $5.95 | +421.01% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $66.15 | -76.57% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.16 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.81 | +452.49% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.67
Upside: +124.72%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $17.82
Upside: +135.69%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.18
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $17.32
Upside: +257.97%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $4.87
Upside: +1,748.05%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.31
Upside: +819.54%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.11
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $27.40
Upside: +356.20%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $7.93
Upside: +240.48%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.13
Upside: +70,696.46%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.06
Upside: +213.15%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.64
Upside: +1,467.40%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.85
Upside: +1,783.02%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $7.64
Upside: +384.29%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $8.95
Upside: +291.06%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $27.69
Upside: +225.03%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $5.95
Upside: +421.01%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $66.15
Upside: -76.57%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.16
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.81
Upside: +452.49%